0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About CardioGenics Holdings
Its shares trade under the ticker CGNH. It has been listed since 9 June 2004.
CardioGenics Holdings, Inc. is a biotechnology company, which engages in the business of development and commercialization of diagnostic test products to the In Vitro Diagnostics testing market. The company is headquartered in Boca Raton, Florida. The company went IPO on 2004-06-09. The firm is engaged in development of technology and products, which include The QL Care Analyzer (QLCA), Cardiovascular Tests and Paramagnetic beads. The QLCA is a point-of-care (POC) immunoassay analyzer. The QLCA uses a self-metering cartridge to perform immunoassay tests at the POC. To support the use of the QLCA, the Company develops approximately four immunoassay tests designed to identify cardiac markers in the blood at the time of a heart attack. Its immunoassay tests include Troponin I (TnI), Plasminogen Activator Inhibitor Type-1 (PAI-1), Heart Failure Risk Stratification (HFRS) and Heart Failure Genomics Risk (HFGR). The firm's TnI test product is in the pilot testing phase. Paramagnetic (magnetic) beads are the solid phase employed during immunoassays tests.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 9 Jun 2004
- Employees
- 7
Leadership
Pay as last reported
- Mr. J.Neil TabatznikDirector/Acting Chairman, since 2009
- Dr. Yahia GawadDirector & Chief Executive Officer, since 2009$119,449
- Mr. James EssexChief Financial Officer$28,668
- Ms. Linda SterlingCorporate Secretary, Director, since 2009$25,078
- Mr. Karim MurabetIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- • CardioGenics Holdings Inc specializes in the development and commercialization of diagnostic tests for cardiovascular diseases, which is a growing market with high demand.
- • The company has a strong product portfolio with innovative and reliable diagnostic technologies that provide accurate results in a timely manner.
- • CardioGenics has established strategic partnerships with leading healthcare organizations, enabling them to access a wider customer base and enhance distribution channels.
Weaknesses
- • The company operates in a highly competitive industry with several established players, which poses a challenge for market penetration and market share growth.
- • CardioGenics may face difficulties in securing sufficient funding for research and development activities, product expansion, and marketing initiatives.
- • The company's limited geographic presence may hinder its ability to reach potential customers in international markets.
Opportunities
- • The increasing prevalence of cardiovascular diseases globally presents significant opportunities for CardioGenics to expand its customer base and increase revenue.
- • The advancement of personalized medicine and targeted therapies opens doors for the development of more specific diagnostic tests, which CardioGenics can capitalize on.
- • Ongoing advancements in technology, such as molecular diagnostics and portable testing devices, provide opportunities for CardioGenics to innovate and diversify its product offerings.
Threats
- • Regulatory approvals and compliance requirements pose a challenge for the introduction and commercialization of new diagnostic tests, potentially delaying time to market.
- • Economic uncertainties and fluctuations in healthcare spending can impact the purchasing power of customers, leading to potential declines in demand for CardioGenics' products.
- • Intellectual property infringement and the emergence of alternative diagnostic technologies may threaten CardioGenics' competitive position and market share.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.